You are required to be logged in to access the full website
User Name: Password:
Click here if you have forgotten your username or password
  • Home
  • Latest News
  • Search
  • About M2 Pharma
  • Subscribe
Business & Finance
Generics
Therapy Areas
Policy & Regulation
Research & Development
People
Policy & Regulation
Veralox Therapeutics Submits IND to US FDA for Phase I Trial of VLX-1005 to Treat Heparin-Inducted Thrombocytopenia
Login
Username:

Password:


Related Headlines

Elephas Biosciences partners Neuberg Diagnostics

Pilot Project between BioCytics and LIDE Biotech

Pharming launches Joenja in Japan for APDS patients aged four and above

PTC to acquire BLA-stage ST-920 Fabry disease programme

ArkBio's IND application for AFC candidate AK0406 approved in China for influenza prophylaxis

Definium Therapeutics reports positive Phase 3 results for DT120 in generalised anxiety disorder

Astorg completes acquisition of Thermo Fisher Scientific's microbiology business

Natera to support Phase 1 trial of Kupando's immunotherapy in advanced skin cancers

Graviton BioScience's Investigational New Drug (IND) application for GV101 cleared for Friedreich's ataxia treatment

Laekna's New Drug Application for LAE002 (afuresertib) accepted by China's NMPA

EIT Pharma's lonafarnib New Drug Application accepted for review by US FDA for chronic hepatitis D treatment

AcuCort publishes Phase IV study results on patient use of Zeqmelit oral film

SoftOx doses first patient in SIS-03 proof-of-concept trial

BSF secures exclusive global commercialisation partnership for ETSYL

Aureka Biotechnologies raises USD100m to build biological world model for drug discovery

Home | Business & Finance | Generics | Therapy Areas | Policy & Regulation | Research & Development | People | Search | About M2 Pharma | Subscribe
Copyright © 2026